Literature DB >> 12614285

Outcomes of renal transplantation following bone marrow transplantation.

Khaled Hamawi1, Margarida De Magalhaes-Silverman, J Andrew Bertolatus.   

Abstract

This single center retrospective study was undertaken to determine the outcome of kidney transplantation (KT) after bone marrow transplantation (BMT) and also to determine the need for immunosuppressive therapy after KT when the BMT marrow donor is the KT donor. Kidney transplantation was performed in 10 patients with BMT nephropathy (BMTN). In six patients, the KT donor was the BMT donor; these individuals were given no long-term immunosuppression. Four other patients received KT from donors who were not the marrow donor (two living donors, two cadaveric donors). After median follow up of 34 months, no patient had an episode of acute rejection. All graft losses (n = 4) resulted from patient death. Three were because of infectious processes, including two infectious deaths in patients not on immunosuppression. Median estimated actuarial patient and graft survival (Kaplan-Meier) was 105 months. We conclude that patients with BMTN who receive KT from their marrow donor do not require immunosuppression. Whether immunosuppressive therapy is given or not, outcome appears to be determined largely by BMT-related immune dysfunction.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12614285     DOI: 10.1034/j.1600-6143.2003.00015.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  8 in total

Review 1.  Translating transplantation tolerance in the clinic: where are we, where do we go?

Authors:  M Goldman; K Wood
Journal:  Clin Exp Immunol       Date:  2009-01-22       Impact factor: 4.330

Review 2.  Kidney transplantation for treatment of end-stage kidney disease after haematopoietic stem cell transplantation: case series and literature review.

Authors:  Akihiro Tsuchimoto; Kosuke Masutani; Kazuya Omoto; Masayoshi Okumi; Yasuhiro Okabe; Takehiro Nishiki; Morihito Ota; Toshiaki Nakano; Kazuhiko Tsuruya; Takanari Kitazono; Masafumi Nakamura; Hideki Ishida; Kazunari Tanabe
Journal:  Clin Exp Nephrol       Date:  2018-12-24       Impact factor: 2.801

Review 3.  Chronic kidney disease after hematopoietic stem cell transplantation.

Authors:  Eric P Cohen; Priya Pais; John E Moulder
Journal:  Semin Nephrol       Date:  2010-11       Impact factor: 5.299

4.  HOXB4 but not BMP4 confers self-renewal properties to ES-derived hematopoietic progenitor cells.

Authors:  Sabrina Bonde; Amy M Dowden; Kun-Ming Chan; William B Tabayoyong; Nicholas Zavazava
Journal:  Transplantation       Date:  2008-12-27       Impact factor: 4.939

Review 5.  Solid organ transplantation following end-organ failure in recipients of hematopoietic stem cell transplantation in children.

Authors:  Kiran Upadhyay; Richard N Fine
Journal:  Pediatr Nephrol       Date:  2013-08-16       Impact factor: 3.714

6.  Immune Reconstitution Kinetics following Intentionally Induced Mixed Chimerism by Nonmyeloablative Transplantation.

Authors:  Nayoun Kim; Hyunji Lee; Junghoon Shin; Young-Sun Nam; Keon-Il Im; Jung-Yeon Lim; Eun-Sol Lee; Young-Nam Kang; Se-Ho Park; Seok-Goo Cho
Journal:  PLoS One       Date:  2015-05-11       Impact factor: 3.240

Review 7.  Chronic kidney disease after liver, cardiac, lung, heart-lung, and hematopoietic stem cell transplant.

Authors:  Sangeeta Hingorani
Journal:  Pediatr Nephrol       Date:  2008-06       Impact factor: 3.714

8.  Allograft and patient survival after sequential HSCT and kidney transplantation from the same donor-A multicenter analysis.

Authors:  Michael Eder; Christoph Schwarz; Michael Kammer; Niels Jacobsen; Masouridi Levrat Stavroula; Morton J Cowan; Tepsiri Chongkrairatanakul; Robert Gaston; Rommel Ravanan; Hideki Ishida; Anette Bachmann; Sergio Alvarez; Martina Koch; Cyril Garrouste; Ulrich A Duffner; Brett Cullis; Nicolaas Schaap; Michael Medinger; Søren Schwartz Sørensen; Eva-Maria Dauber; Georg Böhmig; Heinz Regele; Gabriela A Berlakovich; Thomas Wekerle; Rainer Oberbauer
Journal:  Am J Transplant       Date:  2018-07-13       Impact factor: 8.086

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.